Viewing Study NCT03430895


Ignite Creation Date: 2025-12-24 @ 2:02 PM
Ignite Modification Date: 2025-12-30 @ 11:17 PM
Study NCT ID: NCT03430895
Status: COMPLETED
Last Update Posted: 2021-12-01
First Post: 2018-02-07
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Sponsor: Memorial Sloan Kettering Cancer Center
Organization: